Abstract
The American College of Cardiology Foundation (ACCF), along with key specialty and subspecialty societies, conducted an appropriate use review of common clinical scenarios where cardiac computed tomography (CCT) is frequently considered. The present document is an update to the original CCT/cardiac magnetic resonance (CMR) appropriateness criteria published in 2006, written to reflect changes in test utilization, to incorporate new clinical data, and to clarify CCT use where omissions or lack of clarity existed in the original criteria (1). The indications for this review were drawn from common applications or anticipated uses, as well as from current clinical practice guidelines. Ninety-three clinical scenarios were developed by a writing group and scored by a separate technical panel on a scale of 1 to 9 to designate appropriate use, inappropriate use, or uncertain use. In general, use of CCT angiography for diagnosis and risk assessment in patients with low or intermediate risk or pretest probability for coronary artery disease (CAD) was viewed favorably, whereas testing in high-risk patients, routine repeat testing, and general screening in certain clinical scenarios were viewed less favorably. Use of noncontrast computed tomography (CT) for calcium scoring was rated as appropriate within intermediate- and selected low-risk patients. Appropriate applications of CCT are also within the category of cardiac structural and functional evaluation. It is anticipated that these results will have an impact on physician decision making, performance, and reimbursement policy, and that they will help guide future research.
Original language | English (US) |
---|---|
Pages (from-to) | 1864-1894 |
Number of pages | 31 |
Journal | Journal of the American College of Cardiology |
Volume | 56 |
Issue number | 22 |
DOIs | |
State | Published - Nov 23 2010 |
Externally published | Yes |
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Fingerprint
Dive into the research topics of 'ACCF/SCCT/ACR/AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010 appropriate use criteria for cardiac computed tomography'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Journal of the American College of Cardiology, Vol. 56, No. 22, 23.11.2010, p. 1864-1894.
Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - ACCF/SCCT/ACR/AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010 appropriate use criteria for cardiac computed tomography
AU - Taylor, Allen J.
AU - Cerqueira, Manuel
AU - Hodgson, John Mc B.
AU - Mark, Daniel
AU - Min, James
AU - O'Gara, Patrick
AU - Rubin, Geoffrey D.
N1 - Funding Information: Michael J. Wolk, MD, MACC—Chair, Task Force, Past President, American College of Cardiology Foundation and Clinical Professor of Medicine, Weill-Cornell Medical School, New York, NY Steven Bailey, MD, FACC, FSCAI—Chair, Division of Cardiology, Professor of Medicine and Radiology, Janey Briscoe Distinguished Chair, University of Texas Health Sciences Center, San Antonio, TX Pamela S. Douglas, MD, MACC, FAHA, FASE—Past President, American College of Cardiology Foundation; Past President, American Society of Echocardiography; and Ursula Geller Professor of Research in Cardiovascular Diseases and Chief, Cardiovascular Disease, Duke University Medical Center, Durham, NC Robert C. Hendel, MD, FACC, FAHA, FASNC—Chair, Appropriate Use Criteria for Radionuclide Imaging Writing Group—Director of Cardiac Imaging and Outpatient Services, Division of Cardiology, Miami University School of Medicine, Miami, FL Christopher M. Kramer, MD, FACC, FAHA—Professor of Medicine and Radiology and Director, Cardiovascular Imaging Center, University of Virginia Health System, Charlottesville, VA James Min, MD, FACC—Assistant Professor of Medicine, Weil Cornell Medical College, New York, NY Manesh R. Patel, MD, FACC—Assistant Professor of Medicine, Division of Cardiology, Duke University Medical Center, Durham, NC Leslee Shaw, PhD, FACC, FASNC—Professor of Medicine, Emory University School of Medicine, Atlanta, GA Raymond F. Stainback, MD, FACC, FASE—Medical Director of Noninvasive Cardiac Imaging, Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, TX; Clinical Associate Professor of Medicine, Baylor College of Medicine; President-Elect, Intersocietal Commission for the Accreditation of Echocardiography Laboratories (ICAEL); Hall-Garcia Cardiology Associates, Houston, TX Joseph M. Allen, MA—Director, TRIP (Translating Research into Practice), American College of Cardiology Foundation, Washington, DC Appendix D Funding Information: Committee Member Research Grant Speaker Stock Ownership Salary Board of Directors Consulting Fees/Honoraria Expert Witness Cardiac Computed Tomography Use Criteria Writing Group Manuel Cerqueira • Perceptive Informatics, Inc. • Astellas • GE Healthcare None None None • Astellas • GE Healthcare • MDS Nordion • Siemens None John McB. Hodgson • Boston Scientific • RADI • Volcano Corp None • Guardian VPM None None • Volcano Corp • Myocardial infarct • Review of care delivered to patient with prosthetic valve endocarditis Daniel Mark None None None None None None None James Min None • GE Healthcare None None None None None Patrick O'Gara • Lantheus None None None None None None Geoffery D. Rubin None None • Terarecon None None • Fovia • Medtronic • Trivascular 2 None Allen J. Taylor • Abbott • Resverlogix None None None None • Abbott None Cardiac Computed Tomography Appropriate Use Criteria Technical Panel Daniel Berman • Siemens • GE/Amersham • Astellas • Lantheus None None None None • Astellas • Bracco • Cedars Sinai Medical Center-software royalties • Floura Pharma • Lantheus • Magellan • Spectrum Dynamics None Alan Brown None None None None None • AstraZeneca • Merck • Merck/Schering-Plough • Pfizer • Reliant None Farooq A. Chaudhry • Lantheus • Lantheus None None None None None Ricardo C. Cury • Astellas Pharma • Pfizer Inc. None None None • Society of Cardiovascular Computed Tomography • Astellas Pharma None Milind Y. Desai None • Philips None None None None None Andrew J. Einstein • Spectrum Dynamics None None None None None None Antoinette S. Gomes None None None None None None None Robert Harrington • AstraZeneca • Bristol-Myers Squibb • GlaxoSmithKline • Merck • Millenium • Portola • Schering-Plough • The Medicines Company None None None None • AstraZeneca • Baxter • CSL Behring • Eli Lilly • Heart.org • Luitpold • Merck • Novartis • Otsuka Maryland Research Institute • Regado • Schering-Plough • WebMD None Udo Hoffmann None None None None None None None Rahul Khare None None None None None None None Christopher M. Kramer • Astellas • GlaxoSmithKline • Siemens None None None None None None John Lesser None • Siemens Medical Systems None None None • Vital Images None Christopher McGann None None None None None None None Alan Rosenberg None None None • WellPoint Inc. None None None Robert Schwartz None None None None None None None Marc Shelton None None None None None None None Gerald W. Smetana None None • Anvita Health None None None None Sidney C. Smith, Jr. None None None None None None None Allen J. Taylor • Abbott • Resverlogix None None None None • Abbott None Cardiac Computed Tomography Appropriate Use Criteria Task Force Joseph M. Allen None None None None None None None Steven Bailey • Boston Scientific Corporation None None None None • Volcano None Pamela S. Douglas • Abiomed • Amgen • Atritech • Edwards Lifesciences • MAP Pharmaceuticals • Medtronic • Osiris • Viacor None • Cardio DX • Elsevier None • Translational Research in Oncology • 23andME • BG Medicine • CancerGuideDX • Heart.org • Institute of Medicine • National Institutes of Health • Novartis • Pappas Ventures • Veterans Administration • WebMD • Xceed Molecular None Robert C. Hendel • GE Healthcare • Astellas None None None • PHx Health • United Healthcare None Christopher M. Kramer • Astellas • GlaxoSmithKline • Siemens None None None None None None James Min None • GE Healthcare None None None None None Manesh R. Patel • Genzyme None None None None None None Leslee Shaw • Astellas • Bracco Diagnostics None None None None None None Raymond F. Stainback None None None None None None None Michael J. Wolk None None None None None None None Cardiac Computed Tomography Appropriate Use Criteria Indication Reviewers Michael Atalay None None None None None None None Matthew Budoff None • General Electric None None None None • CT scanning Tracy Callister None • GE Healthcare None None None None None Jefferey Carr None None None None None None None Su Min Chang • Lantheus Imaging None None None None None None Benjamin Cheong • Bracco Inc. • St. Jude Medical None None None None None None Kavitha Chinnaiyan • Bayer Healthcare None None None None None None Philip Costello None None None None None None None E. Gordon DePuey None None None None None None None Andrew J. Einstein • Spectrum Dynamics None None None None None None Lee Fleisher None None None None None • AstraZeneca • Preoperative stroke Mario Garcia • Spectrum Dynamics None • Pfizer None • Intersocietal Accreditation Council • BG Medicine • MD Imaging • TheHeart.org None Thomas Gerber None None None None None None None Raymond Gibbons • Velomedix None None None None • Cardiovascular Clinical Studies (Women Study) • Lantheus Medical Imaging • Medscape ( Heart.org ) • Molecular Insight Pharmaceuticals • TherOx None Harvey Hecht • Philips Medical Systems • Philips Medical Systems None None None None None Milena Henzlova None None • Astellas None None None None Jill Jacobs • Siemens Medical • GE Healthcare None None None None None Scott Jerome • Astellas • Astellas None None None None None Norman Kato None None None None None None None Richard Kovacs None None None None None • Abbott • BG Medicine • Biomedical Systems • Cook Inc-Med Institute • ECG Scanning Services • Eli Lilly • Endocyte • Essentialis • XenoPort None Michael Lauer None None None None None None None John Mahmarian None None None None None None None David Malenka • Abbott Vascular • St. Jude Medical Foundation None None None None None None Frederick A. Masoudi None None None • American College of Cardiology • Oklahoma Foundation for Medical Quality None • United Healthcare (previous) None Julie Miller • Toshiba Medical Systems None None None None None None Debabrata Mukherjee None None None None None None None Meagan Murphy None None None None None None None Jagat Narula None None None None None None None John Nixon None None None None None None None E. Magnus Ohman • Bristol-Myers Squibb • CV Therapeutics • Daiichi Sankyo • Datascope • Eli Lilly • Sanofi-Aventis • Schering-Plough • The Medicines Company • Gilead Sciences None None None • Abiomed • AstraZeneca • CV Therapeutics • Datascope • Gilead Sciences • Liposcience • Northpoint Domain • Pozen, Inc. • Response Biomedical • The Medicines Company • WebMD None Michael H. Picard None None None None None None None Michael Poon None None None None None None None Miguel Quinones None None None None None None None Daniel Rader • Abbott • AstraZeneca • Bristol-Myers Squibb • Merck • Otsuka • AstraZeneca • Merck/Schering-Plough • Merck None None • Isis Pharmaceuticals None Rita Redberg None None None None None None None U. Joseph Schoepf • Bayer-Schering • Bracco • GE • Medrad • Siemens • Bayer • Bracco • GE • Medrad • Merck • Siemens None None None • Bayer-Schering • Bracco • GE • Medrad • Siemens None Samuel Wann None None None None None None None William Guy Weigold • Philips Medical Systems None None None None None None Jonathan Weinsaft None None None None None None None William Weintraub • Abbott • AstraZeneca • Bristol-Myers Squibb • Otsuka • Sanofi-Aventis None None None None • AstraZeneca • Bayer • Bristol-Myers Squibb • Cardionet • Eli Lilly • Pfizer • Sanofi-Aventis • Shionogi • Celebrex litigation • Quetiapine litigation Kim Allan Williams • Bristol-Myers Squibb • PGx Inc. • Astellas None None None • Astellas None This table represents the relationships of the writing group, technical panel, task force, and indication reviewers with industry and other entities. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee and technical panel during the document development process. The table does not necessarily reflect relationships at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% or more of the voting stock or share of the business entity, or ownership of $10 000 or more of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships in this table are modest unless otherwise noted.
PY - 2010/11/23
Y1 - 2010/11/23
N2 - The American College of Cardiology Foundation (ACCF), along with key specialty and subspecialty societies, conducted an appropriate use review of common clinical scenarios where cardiac computed tomography (CCT) is frequently considered. The present document is an update to the original CCT/cardiac magnetic resonance (CMR) appropriateness criteria published in 2006, written to reflect changes in test utilization, to incorporate new clinical data, and to clarify CCT use where omissions or lack of clarity existed in the original criteria (1). The indications for this review were drawn from common applications or anticipated uses, as well as from current clinical practice guidelines. Ninety-three clinical scenarios were developed by a writing group and scored by a separate technical panel on a scale of 1 to 9 to designate appropriate use, inappropriate use, or uncertain use. In general, use of CCT angiography for diagnosis and risk assessment in patients with low or intermediate risk or pretest probability for coronary artery disease (CAD) was viewed favorably, whereas testing in high-risk patients, routine repeat testing, and general screening in certain clinical scenarios were viewed less favorably. Use of noncontrast computed tomography (CT) for calcium scoring was rated as appropriate within intermediate- and selected low-risk patients. Appropriate applications of CCT are also within the category of cardiac structural and functional evaluation. It is anticipated that these results will have an impact on physician decision making, performance, and reimbursement policy, and that they will help guide future research.
AB - The American College of Cardiology Foundation (ACCF), along with key specialty and subspecialty societies, conducted an appropriate use review of common clinical scenarios where cardiac computed tomography (CCT) is frequently considered. The present document is an update to the original CCT/cardiac magnetic resonance (CMR) appropriateness criteria published in 2006, written to reflect changes in test utilization, to incorporate new clinical data, and to clarify CCT use where omissions or lack of clarity existed in the original criteria (1). The indications for this review were drawn from common applications or anticipated uses, as well as from current clinical practice guidelines. Ninety-three clinical scenarios were developed by a writing group and scored by a separate technical panel on a scale of 1 to 9 to designate appropriate use, inappropriate use, or uncertain use. In general, use of CCT angiography for diagnosis and risk assessment in patients with low or intermediate risk or pretest probability for coronary artery disease (CAD) was viewed favorably, whereas testing in high-risk patients, routine repeat testing, and general screening in certain clinical scenarios were viewed less favorably. Use of noncontrast computed tomography (CT) for calcium scoring was rated as appropriate within intermediate- and selected low-risk patients. Appropriate applications of CCT are also within the category of cardiac structural and functional evaluation. It is anticipated that these results will have an impact on physician decision making, performance, and reimbursement policy, and that they will help guide future research.
UR - http://www.scopus.com/inward/record.url?scp=78449313114&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78449313114&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2010.07.005
DO - 10.1016/j.jacc.2010.07.005
M3 - Review article
C2 - 21087721
AN - SCOPUS:78449313114
SN - 0735-1097
VL - 56
SP - 1864
EP - 1894
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 22
ER -